A Phase I/IIa Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD

Trial Profile

A Phase I/IIa Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Carbidopa; Levodopa
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors NeuroDerm
  • Most Recent Events

    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
    • 29 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top